Trials / Completed
CompletedNCT02239237
Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30,283 (actual)
- Sponsor
- Zhong Wang · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This registry aims to monitor the safety of Compound Kuh-seng Injection and to identify the potential risk factors for the adverse drug reactions. Compound Kuh-seng Injection is a kind of natural compound injection extracted from herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae.
Conditions
- Safety Surveillance
- Adverse Drug Events
- Adverse Drug Reactions
- Severe Adverse Events
- Severe Adverse Reactions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Compound Kuh-seng Injection | Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc. |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2018-06-01
- Completion
- 2018-10-01
- First posted
- 2014-09-12
- Last updated
- 2018-10-10
Locations
29 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02239237. Inclusion in this directory is not an endorsement.